MRUS - Merus N.V.
IEX Last Trade
42.055
0.090 0.214%
Share volume: 5,762
Last Updated: Fri 27 Dec 2024 06:29:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$41.96
0.09
0.21%
Fundamental analysis
26%
Profitability
25%
Dept financing
14%
Liquidity
50%
Performance
25%
Performance
5 Days
-0.09%
1 Month
-7.54%
3 Months
-10.13%
6 Months
-25.58%
1 Year
47.98%
2 Year
189.09%
Key data
Stock price
$42.06
DAY RANGE
$41.88 - $43.28
52 WEEK RANGE
$28.24 - $61.46
52 WEEK CHANGE
$50.76
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Sven A. Lundberg
Region: US
Website: merus.nl
Employees: 37
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: merus.nl
Employees: 37
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
Recent news